Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$2.56 - $4.4 $148,241 - $254,790
-57,907 Reduced 21.41%
212,512 $548,000
Q2 2023

Aug 11, 2023

BUY
$1.53 - $4.4 $413,741 - $1.19 Million
270,419 New
270,419 $1.17 Million
Q2 2021

Aug 13, 2021

SELL
$4.45 - $9.91 $481,632 - $1.07 Million
-108,232 Closed
0 $0
Q1 2021

May 11, 2021

SELL
$7.76 - $10.43 $13,603 - $18,283
-1,753 Reduced 1.59%
108,232 $990,000
Q4 2020

Feb 11, 2021

BUY
$4.13 - $10.14 $454,238 - $1.12 Million
109,985 New
109,985 $1.12 Million

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Eam Investors, LLC Portfolio

Follow Eam Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.